|Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease|
JB Canavan, C Scottā, A Vossenkämper, R Goldberg, MJ Elder, I Shoval, ...
Gut 65 (4), 584-594, 2016
|The unusual suspects—innate lymphoid cells as novel therapeutic targets in IBD|
R Goldberg, N Prescott, GM Lord, TT MacDonald, N Powell
Nature reviews Gastroenterology & hepatology 12 (5), 271-283, 2015
|Interleukin 6 increases production of cytokines by colonic innate lymphoid cells in mice and patients with chronic intestinal inflammation|
N Powell, JW Lo, P Biancheri, A Vossenkämper, E Pantazi, AW Walker, ...
Gastroenterology 149 (2), 456-467. e15, 2015
|Seasonal recurrence of food bolus obstruction in eosinophilic esophagitis|
HL Philpott, S Nandurkar, F Thien, S Bloom, E Lin, R Goldberg, ...
Internal medicine journal 45 (9), 939-943, 2015
|Toxicity and response to thiopurines in patients with inflammatory bowel disease|
R Goldberg, PM Irving
Expert review of gastroenterology & hepatology 9 (7), 891-900, 2015
|Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres|
MA Samaan, P Pavlidis, E Johnston, B Warner, J Digby-Bell, ...
Frontline Gastroenterology 8 (3), 196-202, 2017
|Genetic variants alter T-bet binding and gene expression in mucosal inflammatory disease|
K Soderquest, A Hertweck, C Giambartolomei, S Henderson, R Mohamed, ...
PLoS genetics 13 (2), e1006587, 2017
|Correction of defective T-regulatory cells from patients with Crohn’s disease by ex vivo ligation of retinoic acid receptor-α|
R Goldberg, C Scotta, D Cooper, E Nissim-Eliraz, E Nir, S Tasker, ...
Gastroenterology 156 (6), 1775-1787, 2019
|Bortezomib monotherapy in patients with multiple myeloma is associated with reactivation of hepatitis B.|
R Goldberg, E Smith, S Bell, A Thompson, PV Desmond
Internal medicine journal 43 (7), 835-836, 2013
|Thiopurine metabolite testing in inflammatory bowel disease|
R Goldberg, G Moore, G Cunningham, J Schulberg, P Marsh, S Brown, ...
Journal of gastroenterology and hepatology 31 (3), 553-560, 2016
|Recombinant activated factor VII for a warfarinised Jehovah’s Witness with an acute subdural haematoma|
R Goldberg, KJ Drummond
Journal of Clinical Neuroscience 15 (10), 1164-1166, 2008
|Characterization of the pathoimmunology of necrotizing enterocolitis reveals novel therapeutic opportunities|
SX Cho, I Rudloff, JC Lao, MA Pang, R Goldberg, CB Bui, CA McLean, ...
Nature communications 11 (1), 1-19, 2020
|Resolving intestinal fibrosis through regenerative medicine|
R Schwab, R Lim, R Goldberg
Current opinion in pharmacology 49, 90-94, 2019
|How accurate are hospital scales?|
R Goldberg, G Hebbard
The Medical Journal of Australia 194 (12), 665, 2011
|PTH-114 Dedicated endoscopic ibd surveillance list improves adherence to guidelines|
R Goldberg, S Fong, M Samaan, J DigbyBell, E Johnston, S Anderson, ...
Gut 66 (Suppl 2), A262-A263, 2017
|Predictors of sub-therapeutic infliximab or adalimumab trough levels and anti-drug antibodies and their influence on therapeutic decisions|
R Goldberg, L Beswick, D Van Langenberg, B Sally, O Rosella, P Gibson, ...
JOURNAL OF CROHNS & COLITIS 8, S223-S223, 2014
|Significant heterogeneity in management of food bolus obstruction and divergence from ideal management: a large, multicentre study|
H Philpott, P Gibson, S Nandurkar, R Boyapati, A Finch, R Goldberg, E Lin, ...
Journal of Gastroenterology and Hepatology 27, 132-133, 2012
|A Crohn’s disease-associated IL2RA enhancer variant determines the balance of T cell immunity by regulating responsiveness to IL-2 signaling|
R Goldberg, JN Clough, LB Roberts, J Sanchez, S Kordasti, N Petrov, ...
Journal of Crohn's and Colitis, 2021
|Response to LTE 19-01163|
R Goldberg, GM Lord
Gastroenterology, S0016-5085 (19) 41408-X, 2019
|Restoring protective T cell immunity in Crohn's disease: molecular mechanisms and a gut specific regulatory T cell therapy|
King's College London, 2019